1. Home ›
  2. Our Approach ›
  3. Trials ›
  4. Sri Lanka

Sri Lanka

Sri Lanka 2

This will be a cluster randomized, placebo controlled trial to evaluate the protection provided by Mosquito ShieldTM against Aedes-borne dengue, Chikungunya, and Zika virus (DCZV) transmission. The trial will be carried out in Gampaha District, Sri Lanka, which has active seasonal dengue transmission and well-established infrastructure for studying urban dengue fever. Efficacy will be measured through standard household monitoring of Aedes aegypti population densities, while Aedes borne virus transmission will be measured through door-to-door surveillance for active dengue disease and through serological monitoring for DCZV exposure.
 

Study Objectives:

  1. Demonstrate and quantify the protective efficacy of spatial repellent products in reducing the incidence of dengue infection in humans
  2. Confirm and measure the entomological correlates of reduced infection (e.g., a reduction in adult densities and parity rates).
  3. Evaluate the adoption, maintenance, and sustainability of the spatial repellent intervention in the trial clusters.
  4. Quantifying the total number of infections averted using the spatial repellent intervention.
     

Study Population and Location: The trial will occur in3 Medical Officer of Health zones in the district of Gampaha: Kelaniya, Wattala, and Negambo. AEGIS will establish a cohort of 3,570 persons, primarily children 4-16 years of age and adults who have not been previously infected with DCZV who will provide annual blood samples when they are healthy. Additionally, AEGIS anticipates monitoring up to 14,430 residents for active dengue disease.
 

In-Country Project Lead: National Dengue Control Unit - Sri Lanka and RemediumOne

Additionally, social science methodologies and health and market analyses will provide evidence for the acceptability and scalability of implementation. To ensure the spatial repellent is adopted as a complementary vector control tool, findings will be disseminated to the scientific community, end users, and project stakeholders. 

 

This project is made possible thanks to Unitaid funding and support. Unitaid is a global health agency engaged in finding innovative solutions to prevent, diagnose, and treat diseases more quickly, effectively, and for affordable prices, in low- and middle-income countries. Unitaid’s work includes funding initiatives to address major diseases such as HIV/AIDS, malaria, and tuberculosis, as well as HIV co-infections and co-morbidities such as cervical cancer and hepatitis C, and cross-cutting areas, such as fever management. Unitaid is now applying its expertise to address challenges in advancing new therapies and diagnostics for the COVID-19 pandemic, serving as a key member of the Access to COVID Tools Accelerator. Unitaid is hosted by the World Health Organization.